FibroGen

Anti-CTGF Therapy

FibroGen creates first-in-class medicines to treat chronic and life-threatening conditions such as anemia, Duchenne muscular dystrophy, and pancreatic cancer.

Project
Anti-CTGF Therapy
Indications
Fibrosis, Pancreatic Cancer, Duchenne Muscular Dystrophy
Technique
3D Animation
Intro

Wound healing is a normal part of life. However, if this process becomes uncontrolled or impaired, it can lead to the pathological process of Fibrosis.

Sadly, uncontrolled Fibrosis can create scar tissue and affect many different organs leading to tissue or organ dysfunction, or even death.  Fibrogen has developed, pamrevlumab, a first-in-class antibody used to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic disorders.

Challenge

When we meet with clients, we have to break down the science to understand exactly how their drug, platform, or device works.

We then craft a story, that could easily take a lifetime to study, and convey it in a short video targeted to specific audiences. FibroGen was no exception. However, this video was not designed for a general audience, but instead, targeted to the scientific community, scientifically savvy investors, and key opinion leaders. However, that didn’t get us off the hook of making a compelling video. Whether you’re a scientist, a stakeholder or just someone who likes to watch cool videos, we are all driven by stories, and science stories drive everything we do at Ceptor.

Solution

Like an astronaut tethered in outer space, we were inspired to connect FibroGen’s pamrevlumab to the serious disease of Fibrosis.

So we built a 3D world of connective threads between the Mechanism Of Disease and pamrevlumab’s Mechanism of Action. The result was a highly complex but stunning animation paired with a minimalistic score, dramatic sound design, and insightful voice-over to help tell this incredible story.

Next project
Cancer CCR4 Treg Oral Anti-Inflammatory Drug